期刊文献+

C-erbB-2在乳腺癌中表达及与淋巴结转移的关系 被引量:5

The Expression of C - erbB -2 in Breast Cancer and Its Relationship to Lymph Node Metastasis
下载PDF
导出
摘要 目的 探讨C-erbB-2在乳腺癌中的表达及与淋巴结转移的关系。方法 用免疫组织化学ABC法检测48例乳腺癌和10例乳腺良性疾病组织中C-erbB-2的表达。结果 1O例乳腺良性疾病有1例表达阳性(10.00%),而48例乳腺癌中有32例表达阳性(66.67%)。C-erbB-2的表达与淋巴结转移与否无明显相关性,而与肿瘤病理组织类型显著相关。结论 C-erbB-2过表达在乳腺癌发生发展中起一定作用,并可作为判断乳腺癌生物行为的一个有用指标。 Objective To detect the expression of C - erbB - 2 in breast cnacer and its relationship to lymph node metastasis. Methods The expression of C - erbB - 2 in 48 breast cancers and 10 breast benign neoplasms was studied with immunohistochemical ABC method. Results C - erbB - 2 was benign neoplasm specimens (Positive in 1 of 10) ,and it was positive in 32 of 48 breast cancers.The expression of C - erbB - 2 did not correlate with lymph node metastasis, but correlated significantly with Histopathology. Conclusion C - erbB - 2 may play an important role in the process of carcinogenesis in the breast, and be used as a useful marker for the assessment of biological behavior of breast cancer.
作者 王四玲
出处 《河南肿瘤学杂志》 2003年第1期14-15,共2页 Henan Journal of Oncology
关键词 乳腺癌 癌基因蛋白 淋巴结 免疫组织化学 breast carcinoma c - erbB - 2 oncoprotein lymphnode immunohistochemistry
  • 相关文献

参考文献2

二级参考文献2

  • 1Zhou D,Cancer Res,1987年,47卷,22期,6123页
  • 2Lo S H,Cancer Metastasis Rev,1994年,13卷,1期,9页

共引文献78

同被引文献36

  • 1曹亚丽,吴晓波,王忆丽,瞿伟,涂剑宏,雷秋模.乳腺癌组织中c-erbB-2、p53、PCNA和nm23蛋白的表达及其临床意义[J].中国肿瘤临床与康复,2005,12(3):208-211. 被引量:11
  • 2詹镕洲,郑唯强,龚志锦,余永伟,马大烈,黄玲.乳腺肿瘤C-erbB-2表达及预后意义的研究[J].诊断病理学杂志,1994,1(1):23-25. 被引量:9
  • 3胡江辉,赵文健,谢开红,刘保安.乳腺癌激素受体、CerbB-2、P53、nm23基因的表达及与临床病理特征的关系[J].实用医技杂志,2007,14(19):2531-2533. 被引量:3
  • 4Ellis IO, Dowsett M, Bartlett J, et al. Recommendations for HER2 testing in the UK [ J ]. Clin Patho1,2000 ,53 ( 5 ) : 890 - 892.
  • 5Placido SD, Carlomagno C, Laurentiis MD, et al. C - erbB - 2 ex- pression predicts tamoxifen efficacy in breast cancer patients[ J ]. Breast Cancer Res Treat. 1998,52( 1 ) :55 - 64.
  • 6Pegram MD, Pauletti G, Slamon D J, et al. Her 2/neu as a predic- tive marker of response to breast cance therapy[ J ]. Breast Cancer Res Treat, 1998,52( 1 ) :65.
  • 7Hayes DF, Yamauchi H, Broadwater G, et al. Circulating Her- 2/ erbB - 2/neu( Her - 2 ) extracellular domain as a prognostic factor in patients with metastatic breast cancer: cancer and leukemia group B study 8662[J]. Clin Cancer Res,2001,7 (9) :2703 -2711.
  • 8Tanner M, Jarvinen P, Isola J. Amplification of HER -2/neu and topoisomerase Ilalpha in primary and metastatic breast cancer[ J]. Cancer Res,2001,61 (14) :5345 -5348.
  • 9Pienkowski T, Olszewski W, Kraszewska E, et al. Predictive value of HER - 2 receptor, P53, bcl - 2 and bax proteins, MIB - 1 anti- body, estrogene and progesterone receptor expression in breast cancer patients receiving adjuvant tamoxifen [ J ]. Eur .J Cancer, 2002,38 ( Suppl3 ) : S116.
  • 10Vildan Y, Maktav D, Hakan c,et al. Serum e - erbB - 2 oneopro- tein levels are elevated in recurrent and metastatic breast cancer [ J ]. Clinical Bioehemistry ,2000,33 (4) :315 - 317.

引证文献5

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部